2024
Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: Outcomes of the Randomised TRANSCEND Study Through 24 Months
Brodmann M, Gray W, Schneider P, Kurzmann-Guetl K, Schweiger L, Zeller T, Thieme M, Kilaru S, Bachinsky W, Feldman R, Holden A, Varcoe R, Lansky A, Rosenfield K, Investigators T. Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: Outcomes of the Randomised TRANSCEND Study Through 24 Months. European Journal Of Vascular And Endovascular Surgery 2024 PMID: 39615582, DOI: 10.1016/j.ejvs.2024.11.351.Peer-Reviewed Original ResearchFemoropopliteal artery diseasePrimary safetyPrimary patencyTRANSCEND studiesNon-inferiorityArtery diseaseRutherford stage 2Procedure related deathNon-inferiority clinical studyTarget lesion revascularisationTarget vessel revascularisationPaclitaxel coated balloonTarget limb amputationPrimary efficacyEfficacy endpointBinary restenosisClinical studiesFemoropopliteal arteriesSecondary outcomesRelated deathsCoated balloonsPatientsMonthsEfficacyPatency
2004
Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results.
Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Bérégi JP. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Journal Of Invasive Cardiology 2004, 16 Suppl A: 15a-19a. PMID: 23573600.Peer-Reviewed Original ResearchConceptsMean percent diameter stenosisSirolimus-eluting stent groupSerious adverse eventsFemoral artery occlusionPercent diameter stenosisStent groupArtery occlusionAdverse eventsArtery diseaseDiameter stenosisSuperficial femoral artery diseaseSuperficial femoral artery obstructionPoor long-term outcomesSuperficial femoral artery occlusionChronic limb ischemiaFemoral artery diseaseFemoral artery obstructionSuccessful guidewire passageUncoated-stent groupPrimary end pointFemoropopliteal artery diseaseSix-month resultsLong-term outcomesSirolimus-eluting stentsMean lumen diameter
2002
Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease
Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Bérégi J. Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease. Circulation 2002, 106: 1505-1509. PMID: 12234956, DOI: 10.1161/01.cir.0000029746.10018.36.Peer-Reviewed Original ResearchConceptsMean percent diameter stenosisSirolimus-eluting stent groupSerious adverse eventsFemoral artery occlusionPercent diameter stenosisStent groupArtery occlusionAdverse eventsArtery diseaseDiameter stenosisSuperficial femoral artery diseaseSuperficial femoral artery obstructionPoor long-term outcomesSuperficial femoral artery occlusionChronic limb ischemiaFemoral artery diseaseFemoral artery obstructionSuccessful guidewire passageUncoated-stent groupPrimary end pointFemoropopliteal artery diseaseLong-term outcomesSirolimus-eluting stentsMean lumen diameterNitinol self-expanding stents